Table 1.
Characteristics of the patients with CRC-SPM
| Variable | No. of patients (%) |
|---|---|
| Age (years) | |
| ≥60 | 59 (41.5) |
| <60 | 83 (58.5) |
| Sex | |
| Male | 76 (53.5) |
| Female | 66 (46.5) |
| T category | |
| T0–3 | 65 (45.7) |
| T4 | 77 (54.3) |
| N category | |
| N0 | 23 (16.1) |
| N1–2 | 119 (83.9) |
| Location of tumor | |
| Right-sided colon | 54 (38.1) |
| Left-sided colon | 69 (48.5) |
| Rectum | 19 (13.4) |
| Obstruction | |
| Yes | 85 (59.8) |
| No | 57 (40.2) |
| PCI | |
| ≥20 | 17 (11.9) |
| <20 | 125 (88.1) |
| Histology | |
| Adenocarcinoma | 102 (71.9) |
| Mucinous adenocarcinoma and signet ring cell carcinoma | 40 (28.1) |
| CRS | |
| CC-0/1 | 55 (38.7) |
| CC-2 | 87 (61.3) |
| HIPEC | |
| Yes | 63 (44.4) |
| No | 79 (55.6) |
| Perioperative chemotherapy | |
| Yes | 98 (69.1) |
| No | 44 (30.9) |
| Preventive stoma | |
| Yes | 42 (29.6) |
| No | 100 (70.4) |
| KRAS status | |
| mutKRAS | 68 (47.9) |
| wtKRAS | 74 (52.1) |
| BRAF status | |
| mutBRAF | 42 (29.5) |
| wtBRAF | 100 (70.5) |
CRS = cytoreductive surgery, CC = completeness of cytoreduction, HIPEC = hyperthermic intraperitoneal chemotherapy, mutKRAS/wtKRAS = KRAS mutation/KRAS wild-type, mutBRAF/wtBRAF = BRAF mutation/BRAF wild-type.